|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.68 SEK | -2.86% |
|
-42.62% | -82.98% |
| May. 15 | Transcript : Scandion Oncology A/S - Special Call | |
| Mar. 21 | Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival | CI |
Scandion Oncology appointed Dr. Alfredo Zurlo as Chief Medical Officer (CMO). Alfredo Zurlo joins Scandion immediately as part of the company's Executive Management-team. Following his tenure at Roche, Alfredo Zurlo has served as CMO in the two biotech companies Glycotope and Mologen.
Alfredo Zurlo replaces Peter Michael Vestlev, who will continue to work for Scandion in the position of Distinguished Medical Scientist, ensuring an effective handover to Alfredo Zurlo.
| 1st Jan change | Capi. | |
|---|---|---|
| -82.98% | 2.69M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
SCANDION ONCOLOGY A/S 
